ArticleInternational journal of molecular sciences2019
Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.Neoplasia (New York, N.Y.) · 2020Trial
- Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component.Frontiers in oncology · 2025Article
- Interferon-stimulated gene subtypes as key indicators of immune landscape and survival outcomes in ovarian cancer.Discover oncology · 2024Article
- The effect of smoking on tumor immunoediting: Friend or foe?Tobacco induced diseases · 2024Review
- Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.Cancer research and treatment · 2023Article
- Genomic features and its potential implication in bone oligometastatic NSCLC.BMC pulmonary medicine · 2023Article
- Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.Frontiers in oncology · 2022Article
- Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.BioMed research international · 2022Article
- Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.Bioengineered · 2021Article
- Allele frequency deviation (AFD) as a new prognostic model to predict overall survival in lung adenocarcinoma (LUAD).Cancer cell international · 2021Article
- Identification of key genes in the tumor microenvironment of lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2021Article
- Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer.Frontiers in oncology · 2021Article
- GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response.Frontiers in oncology · 2021Article
- Association ofFrontiers in genetics · 2021Article
- Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.Scientific reports · 2020Article
- Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.JAMA network open · 2020Observational
- Differential expression of lung adenocarcinoma transcriptome with signature of tobacco exposure.Journal of applied genetics · 2020Article
- Lessons from the Endoplasmic Reticulum CaCells · 2020Review
- Article
- Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.International journal of medical sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
The distinct molecular subtypes of lung cancer are defined by monogenic biomarkers, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.